The agreement paved the way for TransCode to acquire the parent company of Polynoma from DEFJ, an indirect wholly owned unit of CK Life, the latter said in a filing with the Hong Kong stock exchange after trading hours on Wednesday.
In exchange, TransCode would issue US$125 million worth of new common and non-voting preferred shares to the parent company of Polynoma, CK Life said. These non-voting preferred shares can be converted to common shares subject to the approval of TransCode’s shareholders and relevant Nasdaq rules.
CK Life, through DEFJ, also agreed to invest about US$25 million in TransCode to support the continued development of both Polynoma’s lead therapeutic candidate and TransCode’s pipeline.
Upon completion of the transaction, CK Life will own about 9.1 per cent of TransCode’s outstanding common shares. Meanwhile, the full conversion of preferred shares to common shares will give CK Life about a 90.7 per cent stake in TransCode’s outstanding common shares.
